Micronized progesterone: Clinical indications and comparison with current treatments

Fertility and Sterility

Volumn 72, Issue 3, 1999, Pages 389-397

  Fitzpatrick, Lorraine A ^a   Good, Andrew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hormone replacement therapy; Luteal phase dysfunction; Micronized progesterone; Premature labor; Premenopausal dysfunction; Secondary amenorrhea

Indexed keywords

PROGESTERONE;

ADULT; AFFECTIVE NEUROSIS; BIOAVAILABILITY; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LUTEAL INSUFFICIENCY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PREMATURE LABOR; PREMENOPAUSE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PUERPERAL DEPRESSION; RECTAL DRUG ADMINISTRATION; REVIEW; SECONDARY AMENORRHEA; SUPPOSITORY; UNITED STATES;

AMENORRHEA; BIOLOGICAL AVAILABILITY; DOSAGE FORMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INFERTILITY, FEMALE; MENSTRUATION DISTURBANCES; PREGNANCY; PROGESTERONE;

EID: 0033198821     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(99)00272-1     Document Type: Review

References (74)

1. Simon J.A. Micronized progesterone vaginal and oral uses. Clin Obstet Gynecol. 38:1995;902-904.
2. Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception. 54:1996;59-69.
3. Fotherby K. Potency and pharmacokinetics of gestogens. Contraception. 41:1990;533-550.
4. Perone N. The progestins. Goldzieher J.W., Pharmacology of the contraceptive steroids. 1994;5-19 Raven Press, New York.
5. Bardin C.W. The androgenic, antiandrogenic and synandrogenic actions of progestins. Progesterone and progestins. 1983;135-161 Raven Press, New York.
6. De Souza M.J., Prestwood K.M., Luciano A.A., Miller B.E., Nulsen J.C. A comparison of the effect of synthetic and micronized hormone replacement on bone mineral density and biochemical markers of bone metabolism. Menopause. 3:1996;140-148.
7. Maxson W.S., Hargrove J.T. Bioavailability of oral micronized progesterone. Fertil Steril. 44:1985;622-626.
8. Nahoul K., Dehennin L., Scholler R. Radioimmunoassay of plasma progesterone after oral administration of micronized progesterone. J Steroid Biochem. 26:1987;241-249.
9. Hargrove J.T., Maxson W.S., Wentz A.C. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol. 161:1989;948-951.
10. Carr B.R., Wilson J.D. Disorders of the ovary and female reproductive tract. Isselbacher K.J., Harrison's principles of internal medicine. 1994;2017-2036 McGraw-Hill, New York.
11. Progestins. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, 1996:1426-40.
12. Whitehead M.I., Hillard T.C., Crook D. The role and use of progestogens. Obstet Gynecol. 75:1990;59S-76S.
13. Spellacy W.N. A review of carbohydrate metabolism and the oral contraceptives. Am J Obstet Gynecol. 104:1969;448-460.
14. Tikkanen M.J., Kuusi T., Nikkila E.A., Sipinen S. Post-menopausal hormone replacement therapy effects of progestogens on serum lipids and lipoproteins: a review. Maturitas. 8:1986;7-17.
15. Newnham H.H. Oestrogens and atherosclerotic vascular disease lipid factors. Baillieres Clin Endocrinol Metab. 7:1993;61-93.
16. Lobo R.A., Pickar J.H., Wild R.A., Walsh B., Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol. 84:1994;987-995.
17. King R.J.B., Whitehead M.I. Assessment of the potency of orally administered progestins in women. Fertil Steril. 46:1986;1062-1066.
18. Gibbons W.E., Moyer D.L., Lobo R.A., Roy S., Mishel D.R. Jr. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol. 154:1986;456-461.
19. Barnes R.B., Roy S., Lobo R.A. Comparison of lipid androgen levels after conjugated estrogen or dep-medroxyprogesterone acetate treatment in postmenopausal women. Obstet Gynecol. 66:1985;216-219.
20. Nillius S.J., Johansson E.D. Plasma levels of progesterone after vaginal, rectal or intramuscular administration of progesterone. Am J Obstet Gynecol. 110:1971;470-477.
21. Ottosson U.B., Carlstrom K., Damber J.E., von Schoultz B. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parental administration. Br J Obstet Gynaecol. 91:1984;1111-1119.
22. Arafat E.S., Hargrove J.T., Maxson W.S., Desiderio D.M., Wentz A.C., Andersen R.N. Sedative and hypnotic effect of oral administration of micronized progesterone may be mediated through its metabolites. Am J Obstet Gynecol. 159:1988;1203-1209.
23. Lobo R.A. Absorption and metabolic effects of different types of estrogens and progestogens. Obstet Gynecol Clin North Am. 14:1987;143-167.
24. Sitruk-Ware R., Bricaire C., de Lignieres B., Yaneva H., Mauvais-Jarvis P. Oral micronized progesterone. Contraception. 36:1987;373-401.
25. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation: update 1993. In: Horwitz KB, ed. Endocrine reviews monographs 1. Endocrine aspects of cancer. Bethesda, MD: The Endocrine Society, 1993:132-5.
26. Aufrere M.B., Benson H. Progesterone an overview and recent advances. J Pharm Sci. 65:1976;783-800.
27. Mauvais-Jarvis P. Progesterone and progestins a general overview. Bardin D.W., Milgrom E., Mauvais-Jarvis,. Progesterone and progestins. 1983;1-16 Raven Press, New York.
28. Bayard F., Damilano S., Robel P., Baulieu E.E. Cytoplasmic and nuclear estradiol and progesterone receptors in human endometrium. J Clin Endocrinol Metab. 46:1978;635-648.
29. MacLusky N.J., McEwen B.S. Progestin receptors in rat brain distribution and properties of cytoplasmic progestin-binding sites. J Clin Endocrinol Metab. 106:1980;192-202.
30. Adlecreutz H., Martin F. Biliary excretion and intestinal metabolism of progesterone and estrogens in man. J Steroid Biochem. 13:1980;231-244.
31. Whitehead M.I., Townsend P.T., Gill D.K., Collins W.P., Campbell S. Absorption and metabolism of oral progesterone. Br Med J. 280:1980;825-827.
32. McAuley J.W., Kroboth F.J., Kroboth P.D. Oral administration of micronized progesterone a review and more experience. Pharmacotherapy. 16:1996;453-457.
33. Simon J.A., Robinson D.E., Andrews M.C., Hildebrand J.R., Rocci M.L., Blake R.E., et al. The absorption of oral micronized progesterone the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril. 60:1993;26-33.
34. Simon J.A., Shangold M.M., Andrews M.C., Buster J.E., Hodgen G.D. Administration de la progestérone micronisée impact de la voie d'administration et des données cinétoques sur les applications cliniques. Contracept Fertil Sex. 20:1992;1031-1037.
35. Padwick M., Endacott J., Whitehead M. Pharmacokinetics of oral micronized progesterone. Maturitas. 6:1984;161-165.
36. Nahoul K., Dehennin L., Jondet M., Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas. 16:1993;185-202.
37. Bulletti C., de Ziegler D., Flamigni C., Giacomucci E., Polli V., Bolelli G., et al. Targeted drug delivery in gynaecology the first uterine pass effect. Hum Reprod. 12:1997;1073-1079.
38. Shangold M.M., Tomai T.P., Cook J.D., Jacobs S.L., Zinaman M.J., Chin S.Y., et al. Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril. 56:1991;1040-1047.
39. Saarikoski S., Yliskoski M., Penttilä I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas. 12:1990;89-97.
40. Devroey P., Smitz J., Bourgain C., Camus M., Van Steirteghem A. La progesterone micronisee est la methode de choix pour la supplemetation luteale au cours des cycles stimules par agonistes de la lhrh. Contracept Fertil Sex. 19:1991;597-600.
41. Devroey P., Smitz J., Bourgain C., Van Steirteghem A. Seula la progestérone micronisée est nécessaire pour substituer la phase lutéale au cours des cycles stimulés. Contracept Fertil Sex. 20:1992;1021-1024.
42. Frishman G.N., Klock S.C., Luciano A.A., Nulsen J.C. Efficacy of oral micronized progesterone in the treatment of luteal phase defects. J Reprod Med. 40:1995;521-524.
43. Pouly J.L., Bassil S., Frydman R., Hedon B., Nicollet B., Prada Y., et al. Luteal support after in-vitro fertilization Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Hum Reprod. 11:1996;2085-2089.
44. Wang H.S., Soong Y.K. Transvaginal progesterone supplementation increases serum insulin-like growth factor-binding protein-1 levels. Gynecol Endocrinol. 10:1996;349-355.
45. Chan C.L.K., Ng S.C., Goh V., Bongso T.A., Devandra S., Ratnam S.S. Profils hormonaux et histologie de l'endometre sous l'effect de la substitution hormonale cyclique par la progesterone micronisee (Utrogestan). Contracept Fertil Sex. 19:1991;600-606.
46. Devroey P., Palermo G., Bourgain C., Van Waesberghe L., Smitz J., Van Steirteghem A.C. Progesterone administration in patients with absent ovaries. Int J Fertil. 34:1989;188-192.
47. Erny R., Pigne A., Prouvost C., Gamerre M., Malet C., Serment H., et al. The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol. 154:1986;525-529.
48. Noblot G., Audra P., Dargent D., Faguer B., Mellier G. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol. 40:1991;203-209.
49. Magnin G., de Meeus J.B., Sarfati R., Chaouchi O., Paillat A. Hepatitis caused by micronized natural progesterone given for preterm labor. Presse Med. 25:1996;102-105.
50. Benifla J.L., Dumont M., Levardon M., Foucher E., Cadiot G., Crenn-Hebert C., et al. Effects of natural micronized progesterone on the liver during the third trimester of pregnancy. Contracept Fertil Sex. 25:1997;165-169.
51. Lobo R. The role of progestins in hormone replacement therapy. Am J Obstet Gynecol. 166:1992;1997-2004.
52. Newnham H.H. Oestrogens and atherosclerotic vascular disease lipid factors. Baillieres Clin Endocrinol Metab. 7:1993;61-93.
53. Lane M.B., Siddle N.C., Ryder T.A., Pryse-Davies J., King R.J.B., Whitehead M.I. Dose dependent effects of oral progesterone on the estrogenized postmenopausal endometrium. Br Med J. 287:1983;1241-1245.
54. Kim S., Korhonen M., Wilborn W., Foldesy R., Snipes W., Hodgen G., et al. Antiproliferative effects of low-dose micronized progesterone. Fertil Steril. 65:1996;323-331.
55. Moyer D., de Lignieres B., Driguez P., Pierre J. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement influence of bleeding pattern and secretory changes. Fertil Steril. 59:1993;992-997.
56. Bolaji I., Grimes H., Mortimer G., Tallon D., Fottrell P., O'Dwyer E. Low-dose progesterone therapy in oestrogenised postmenopausal women effects on plasma lipids, lipoproteins and liver function parameters. Eur J Obstet Gynecol. 48:1993;61-68.
57. Moorjani S., Dupont A., Labrie F., de Lignieres B., Cusan L., Dupont P., et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with Utrogestan in menopausal women. J Clin Endocrinol Metab. 73:1991;373-379.
58. Darj E., Axelsson O., Carström K., Nilsson S., von Schoultz B. Liver metabolism during treatment with estradiol and natural progesterone. Gynecol Endocrinol. 7:1993;111-114.
59. Espeland M., Bush T., Mebane-Sims I., Stefanick M., Johnson S., Sherwin R., et al. Rationale, design and conduct of the PEPI trial. Control Clin Trials. 16:1995;3S-19S.
60. Johnson S., Mebane-Sims I., Hogan P., Stoy D. Recruitment of postmenopausal women in the PEPI trial. Control Clin Trials. 16:1995;20S-35S.
61. Miller V., Byington R., Espeland M., Langer R., Marcus R., Shumaker S., et al. Baseline characteristics of the PEPI participants. Control Clin Trials. 16:1995;54S-65S.
62. Espeland M., Marcovina S., Miller V., Wood P.D., Wasilauskas C., Sherwin R., et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation. 97:1998;979-986.
63. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 273:1995;199-208.
64. Barrett-Connor E., Slone S., Greendale G., Kritz-Silverstein D., Espeland M., Johnson S.R., et al. The postmenopausal estrogen/progestin interventions study primary outcomes in adherent women. Maturitas. 27:1997;261-274.
65. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA. 276:1996;1389-1396.
66. Philippe E., Faguer B., Engelman A., Charpin C., Loubiére R., de Mascarel A., et al. L'endométre sous traitement hormonal substitutif de la méenopause par estradiol percutané et progestérone micronisée à faible dose. Pathologica. 85:1993;475-487.
67. Gillet J.Y., Andre G., Faguer B., Erny R., Buvat-Herbaut M., Domin M.A., et al. Induction of amenorrhea during hormone replacement therapy optimal micronized progesterone dose. A multicenter study. Maturitas. 19:1994;103-115.
68. Bolaji I.I., Mortimer G., Grimes H., Tallon D.F., O'Dwyer E., Fottrell P.F. Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women. Gynecol Endocrinol. 10:1996;41-47.
69. Minshall R.D., Stanczyk F.Z., Miyagawa K., Uchica B., Axthelm M., Novy M., et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab. 83:1998;649-659.
70. Guidotti A., Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3α, 5α-tetrahydroprogesterone (allopregnanolone) availability. Biol Psychiatry. 44:1998;865-873.
71. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 232:1986;1004-1007.
72. de Lignieres B., Dennerstein L., Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas. 21:1995;251-257.
73. Freeman E.W., Purdy R.H., Coutifaris C., Rickels K., Paul S.M. Anxiolytic metabolites of progesterone correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology. 58:1993;478-484.
74. Freeman E.W., Rickels K., Sondheimer S., Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA. 274:1995;51-57.